Papers of the Week

Immune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1). The spectrum of immunotherapy-induced adverse reactions is unique and referred as immune-related adverse events (irAEs). Cutaneous toxicities account for approximately 30% of all irAEs; the most common include eczema-like maculopapular rash, pruritus, lichenoid reactions, vitiligo-like lesions, psoriasis, and, less frequently, bullous pemphigoid or sarcoidosis. Sclerotic reactions as scleroderma and morphea have been rarely described. A recent review reported 6 cases of scleroderma and 4 cases of morphea. We describe two cases of ICI-related morphea-like reactions.